Fifteen-year follow-up from the SWOG S0016 trial indicates that a subset of patients with advanced-stage FollicularLymphoma can achieve cure after first-line chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and anti-CD20 therapy.

Cure modeling estimated an overall cure rate of 42%, with relapse rates substantially declining over time and highest cure likelihood in patients with low Follicular Lymphoma International Prognostic Index scores and normal β2 microglobulin levels.

This secondary analysis examines 15-year follow-up data from a randomized clinical trial to evaluate the potential for long-term remission and cure for follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)–based regimens.